New Treatment Strategy Proposed for Some Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

SERENA-6 is the first global registration phase 3 trial to demonstrate the clinical utility of ctDNA monitoring to ...

JUNE 16, 2025